Kodeks u kliničkom i
eksperimentalnom radu |
| Home page | Editorial board | About the Journal | Instructions for Authors | Peer Review Policy | Clinical and Experimental Work Code | Contact |
Clinical Center Niš
Clinic for Cardiovascular Diseases
Bul. Dr Zorana Djindjića 48
18000 Niš, Serbia
Tenecteplase AS a new medication IN Managing No-Reflow
Milan Živković, Svetlana Apostolović, Milan Pavlović, Sonja Šalinger Martinović, Tomislav Kostić, Nenad Božinović and Emina Dimitrijević
Clinical Center Niš, Clinic for Cardiovascular Diseases
No-reflow has been defined as “inadequate myocardial perfusion through a given segment of coronary circulation without angiographic evidence of a mechanical obstruction”. Important components of the process are thought to include endothelial ischemic injury producing “blebs” of tissue that directly obstruct the microvasculature, leukocyte plugging of capillaries, and the vascular effects of reactive oxygen species. No-reflow can complicate any percutaneous intervention (PCI), though it is more common following acute myocardial infarctions (MI), particularly with prolonged occlusion times.
A 59-year-old woman presented to the hospital after two hours of continuous chest pain. Because of acute myocardial infarction of the inferior and lateral wall, she underwent direct stenting to an occlusion in the right coronary artery. Despite successful implantation of stents revascularization failed. In absence of aspiration devices and other pharmacological agent we decide to apply 30 mg (6000 IU) tenecteplase intracoronary. Three min after administration TIMI flow grade improved from TIMI 0 to TIMI 3.
Managing no-reflow can be approached in a number of different ways and needs to be tailored to the type of intervention being performed. As confirmed in practice, prevention is better than cure and both mechanical and pharmacological approaches can be employed in high risk cases. In the setting of acute myocardial infarction the most effective preventative measure is the rapid opening of the vessel and as such the development of a robust and efficient primary PCI service is integral to the avoidance of this complication.
Managing no-reflow will become increasingly important with the wider development of primary PCI. Within the setting of acute myocardial infarctions with no reflow as primary percutaneous intervention complication, there are potential important future pharmacological regimens that may become established and one of them can be tenecteplase. Acta Medica Medianae 2012; 51(1):42-45.
Key words: no-reflow, acute myocardial infarction, primary PCI, tenecteplase